Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Director Theodore R. Samuels II acquired 884.017 deferred share units of Bristol-Myers Squibb on December 31, 2024, convertible to common stock upon settlement.

Summary

• Theodore R. Samuels II, a director at Bristol-Myers Squibb, acquired 884.017 deferred share units on December 31, 2024.
• These deferred share units will convert into shares of common stock upon settlement.
• The settlement of these units will occur when Mr. Samuels ceases to be a director or at a previously specified future date.
• The price of the underlying common stock at the time of the transaction was $56.56 per share.
• Following this transaction, Mr. Samuels beneficially owns 52,748.604 deferred share units, including deferred compensation and reinvested dividends.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, indicating a positive alignment of interests between the director and shareholders. It is not a major event but is a positive sign of director engagement.

Positives

• The acquisition of deferred share units by a director signals confidence in the company's future performance.
• The director's increased stake aligns his interests with those of other shareholders.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the director ceases to be a director or at a previously specified future date.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It reflects the compensation structure for directors and their alignment with shareholder interests.

Comparison to Industry Standards

• Deferred share unit grants are a common form of compensation for directors in publicly traded companies, particularly in the pharmaceutical industry.
• Many companies, such as Pfizer (PFE) and Merck (MRK), also use similar equity-based compensation plans for their directors.
• The vesting and settlement terms are typical, with settlement often tied to the director's tenure or a pre-determined date.

Stakeholder Impact

• The transaction increases the director's stake in the company, aligning his interests with those of shareholders.
• This type of transaction is generally viewed positively by investors as it demonstrates director confidence in the company.

Next Steps

• The deferred share units will be converted into common stock upon settlement at a future date.

Key Dates

Keywords

Deferred Share Units, Director, Insider Trading, Beneficial Ownership, Bristol-Myers Squibb, BMY, SEC Form 4